GARDASIL INJECTABLE SUSPENSION
How to use GARDASIL INJECTABLE SUSPENSION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Gardasil, injectable suspension
Human Papillomavirus [Types 6, 11, 16, 18] (Recombinant, adsorbed) vaccine
Read all of this leaflet carefully before you or your child is vaccinated
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack:
- What is Gardasil and what is it used for
- What you need to know before you receive Gardasil
- How Gardasil is administered
- Possible side effects
- Storage of Gardasil
- Contents of the pack and further information
1. What is Gardasil and what is it used for
Gardasil is a vaccine. Vaccination with Gardasil is indicated to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18.
These diseases include precancerous lesions of the female genital area (cervix, vulva, and vagina); precancerous lesions of the anus and genital warts in men and women; anal and cervical cancer. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases; 75-80% of anal cancer cases; 70% of vulvar and vaginal precancerous lesions related to HPV; 75% of anal precancerous lesions related to HPV. HPV types 6 and 11 are responsible for approximately 90% of genital warts cases.
Gardasil is indicated to prevent these diseases. The vaccine is not used to treat HPV-related diseases. Gardasil has no effect on individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the HPV types in the vaccine, Gardasil may still protect against diseases associated with the other HPV types in the vaccine.
Gardasil cannot cause the diseases it protects against.
Gardasil induces the production of specific antibodies and has been shown in clinical trials to prevent HPV 6, 11, 16, and 18-related diseases in women aged 16-45 and men aged 16-26. The vaccine also induces the production of specific antibodies in children and adolescents aged 9-15.
Gardasil should be used according to official recommendations.
2. What you need to know before you receive Gardasil
You should not receive Gardasil if:
- you or your child is allergic (hypersensitive) to any of the active substances or other components of Gardasil (listed in “other components are” - see section 6).
- you or your child developed an allergic reaction after receiving a dose of Gardasil.
- you or your child has a high fever. However, moderate fever or upper respiratory tract infection (e.g., a cold) does not justify delaying vaccination.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before vaccination if you or your child:
- has a coagulation disorder (a disease that causes bleeding more than normal), e.g., hemophilia.
- has a weakened immune system, e.g., due to a genetic disorder, HIV infection, or medications that affect the immune system.
After any injection with a needle, fainting may occur, mainly in adolescents, sometimes accompanied by falling. Therefore, inform your doctor or nurse if you have fainted with any previous injection.
As with any vaccine, Gardasil does not guarantee 100% protection in all vaccinated individuals.
Gardasil does not protect against all types of Human Papillomavirus. Therefore, appropriate measures to prevent sexually transmitted diseases should continue to be used.
Gardasil does not protect against other diseases not caused by Human Papillomavirus.
Vaccination is not a substitute for routine cervical screening. Do not stop following your doctor's advice about Pap tests/cervical cytology and other preventive and protective measures.
What other important information should you or your child know about Gardasil
Long-term follow-up studies have been conducted to determine the duration of protection. There is no established need for a booster dose.
Use of Gardasil with other medicines or vaccines
Gardasil can be administered with a Hepatitis B vaccine or with a combined booster vaccine of diphtheria (d) and tetanus (T) with pertussis (acellular component) (ap) and/or poliomyelitis (inactivated) (IPV) (dTap, dT-IPV, dTap-IPV vaccines) during the same visit, in a different injection site (another part of the body, e.g., the other arm or leg).
Gardasil may not have an optimal effect if:
- it is used with medications that suppress the immune system.
In clinical trials, oral contraceptives (e.g., the pill) or other methods did not reduce the protection obtained with Gardasil.
Tell your doctor or pharmacist if you or your child is taking or has recently taken or might take any other medicines, including those obtained without a prescription.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Gardasil can be administered to women who are breastfeeding or will be breastfeeding.
Driving and using machines
No studies have been conducted on the effects on the ability to drive and use machines.
Gardasil contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, i.e., it is essentially “sodium-free”.
3. How Gardasil is administered
Your doctor will administer Gardasil via injection. Gardasil is indicated for adolescents and adults from 9 years of age.
If you are between 9 and 13 years old (inclusive)
Gardasil can be administered following a 2-dose schedule:
- First injection: on a given date.
- Second injection: 6 months after the first injection.
If the second dose is administered before 6 months after the first dose, a third dose should be administered.
Alternatively, Gardasil can be administered following a 3-dose schedule:
- First injection: on a given date.
- Second injection: 2 months after the first injection.
- Third injection: 6 months after the first injection.
The second dose should be administered at least 1 month after the first dose, and the third dose should be administered at least 3 months after the second dose. All three doses should be administered within a 1-year period. Consult your doctor for more information.
If you are 14 years old or older
Gardasil should be administered following a 3-dose schedule:
- First injection: on a given date.
- Second injection: 2 months after the first injection.
- Third injection: 6 months after the first injection.
The second dose should be administered at least 1 month after the first dose, and the third dose should be administered at least 3 months after the second dose. All three doses should be administered within a 1-year period. Consult your doctor for more information.
It is recommended that individuals who received a first dose of Gardasil complete the vaccination regimen with Gardasil.
Gardasil will be administered via intramuscular injection through the skin into the muscle (preferably in the upper arm or thigh).
The vaccine should not be mixed in the same syringe with any other vaccine or solution.
If you miss a dose of Gardasil
If you miss a scheduled injection, your doctor will decide when to administer the missed dose.
It is important that you follow your doctor's or nurse's instructions regarding visits for the administration of the following doses. If you miss them or cannot attend your doctor's office at the scheduled time, consult your doctor. If the first dose of vaccine you receive is Gardasil, the completion of the vaccination regimen should be done with Gardasil and not with another HPV vaccine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
As with all vaccines, this vaccine can cause side effects, although not everybody gets them.
The following side effects may appear after use of Gardasil:
Very common(may affect more than 1 in 10 patients), local side effects at the injection site including: pain, swelling, and redness. Headache has also been reported.
Common(may affect more than 1 in 100 patients), local side effects at the injection site including: bruising, itching, pain in the extremity. Fever and nausea have also been reported.
Rare(may affect less than 1 in 1,000 patients), hives.
Very rare(may affect less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported.
More cases of headache and swelling at the injection site have been observed when Gardasil and a combined booster vaccine of diphtheria, tetanus, pertussis (acellular component), and poliomyelitis (inactivated) are administered during the same visit.
Side effects that have been reported during the marketing of Gardasil include:
Fainting, sometimes accompanied by trembling or stiffness. Although fainting episodes are rare, patients should be observed for 15 minutes after receiving the HPV vaccine.
Allergic reactions, which can include difficulty breathing, wheezing, hives, and rash. Some of these reactions have been severe.
As with other vaccines, side effects that have been reported during general use include: swollen lymph nodes (neck, armpit, or groin); muscle weakness, abnormal sensations, tingling in the arms, legs, and upper body, or confusion (Guillain-Barré syndrome, acute disseminated encephalomyelitis); dizziness, vomiting, joint pain, muscle pain, unusual tiredness or weakness, chills, general malaise, bleeding or bruising more easily than normal, and skin infection at the injection site.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Gardasil
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month stated.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Keep the vial in the outer packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Container Contents and Additional Information
Gardasil Composition
The active ingredients are: highly purified non-infectious protein for each type of Human Papillomavirus (6, 11, 16, and 18).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus L1 Protein | Type 6 | 20 micrograms |
Human Papillomavirus L1 Protein | Type 11 | 40 micrograms |
Human Papillomavirus L1 Protein | Type 16 | 40 micrograms |
Human Papillomavirus L1 Protein | Type 18 | 20 micrograms |
- Human Papillomavirus = HPV
- L1 protein in the form of virus-like particles produced in yeast cells
(Saccharomyces cerevisiaeCANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
- Adsorbed on amorphous aluminum hydroxyphosphate sulfate as an adjuvant (0.225 milligrams of Al).
Amorphous aluminum hydroxyphosphate sulfate is included in the vaccine as an adjuvant. Adjuvants are included in some vaccines to accelerate, enhance, and/or prolong the immune response of the vaccines.
The other components of the vaccine suspension are:
Sodium chloride, histidine, polysorbate 80, borax, and water for injectable preparations.
Product Appearance and Container Contents
1 dose of Gardasil injectable suspension contains 0.5 ml.
Before shaking, Gardasil may appear as a clear liquid with a white precipitate.
After vigorous shaking, it is a white and turbid liquid.
Gardasil is available in packs of 1, 10, or 20 vials.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
MSD VACCINS
162 avenue Jean Jaurès
69007 Lyon
France
Manufacturer:
Merck Sharp & Dohme BV
Waarderweg 39
2031 BN Haarlem
Netherlands
For further information on this medicinal product, please contact the local representative of the Marketing Authorization Holder.
Belgium MSD Belgium BVBA/SPRL Tel: +32 (0) 27766211 | Lithuania UAB Merck Sharp & Dohme Tel.: +370.5.2780.247 |
Bulgaria Merck Sharp & Dohme Bulgaria EOOD Tel.: + 359 2 819 3737 | Luxembourg MSD Belgium BVBA/SPRL Tel: +32 (0) 27766211 |
Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 | Hungary MSD Pharma Hungary Kft. Tel.: + 36.1.888.5300 |
Denmark MSD Danmark ApS Tlf: + 45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited. Tel: 8007 4433 (+356 99917558) |
Germany MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 2612) | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Estonia Merck Sharp & Dohme OÜ Tel.: +372 6144 200 | Norway MSD (Norge) AS Tlf: +47 32 20 73 00 |
Greece MSD Α.Φ.Β.Ε.Ε. Tel: +30 210 98 97 300 | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Poland MSD Polska Sp. z o.o. Tel.: +48.22.549.51.00 |
France MSD VACCINS Tél: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Croatia Merck Sharp & Dohme d.o.o. Tel: +385 1 66 11 333 | Romania Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386.1.520.4201 |
Iceland Vistor hf. Tel: + 354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o Tel: +421 2 58282010 |
Italy MSD Italia S.r.l. Tel: +39 06 361911 | Finland MSD Finland Oy Tel: +358 (0)9 804 650 |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvia SIA Merck Sharp & Dohme Latvija Tel: +371.67364.224 | United Kingdom Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 |
Date of Last Revision of this Leaflet:{MM/YYYY}
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu
----------------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only:
The vaccine should be administered as supplied; no dilution or reconstitution is required. The recommended full dose of the vaccine should be used. Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.
Shake well before use. Vigorous shaking immediately before administration is necessary to maintain the suspension of the vaccine.
Parenteral drugs should be inspected visually for particulate matter and discoloration prior to administration. The product should be discarded if it contains particulate matter or appears discolored.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to GARDASIL INJECTABLE SUSPENSIONDosage form: INJECTABLE, 20 µg / 40 µg / 40 µg / 20 µgActive substance: papillomavirus (human types 6, 11, 16, 18)Manufacturer: Merck Sharp & Dohme B.V.Prescription requiredDosage form: INJECTABLE, 20 µg / 40 µg / 40 µg / 20 µgActive substance: papillomavirus (human types 6, 11, 16, 18)Manufacturer: Merck Sharp & Dohme B.V.Prescription requiredDosage form: INJECTABLE, 20 µg / 40 µg / 40 µg / 20 µgActive substance: papillomavirus (human types 6, 11, 16, 18)Manufacturer: Sanofi Pasteur Msd S.N.C.Prescription required
Online doctors for GARDASIL INJECTABLE SUSPENSION
Discuss questions about GARDASIL INJECTABLE SUSPENSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
